A new study is showing that providing Part D Medicare coverage for Novo Nordisk’s semaglutide to reduce cardiovascular disease risk in certain patients could cost the United States Government around $145 billion annually, according to new research published Tuesday in the Annals of Internal Medicine. Semaglutide, which is branded as Ozempic for type 2 diabetes and…